Researchers used DNA microarray technology to identify seven major subtypes of pediatric acute lymphoblastic leukemia, including six known prognostic subtypes. This discovery enables more accurate diagnoses and personalized treatment plans based on a patient's unique expression profile.
A recent study identified 35 genes that may be linked to prognosis in pediatric acute myeloid leukemia (AML), providing new insights into the disease. These unexpected genes were found independently of current classification methods and separated patients into high- and low-risk groups.
Researchers found that administering hydroxyurea to patients with severe forms of beta-thalassemia boosted hemoglobin levels and enabled five patients to stop undergoing transfusions. The treatment also improved quality of life for the children, who reported feeling better and more active.
Researchers developed a gene therapy technique that uses an oncoretrovirus to transfer MGMT into normal bone marrow cells, allowing for the enrichment of healthy cells. The treatment showed promising results in mice with beta-thalassemia, achieving successful in vivo selection in 66% of cases.
Researchers found that patients with a negative pretransplantation scan had a favorable outcome, with 25 still in complete remission after a median follow-up of 1,510 days. In contrast, patients with a positive scan relapsed more frequently, highlighting the potential for [F]FDG-PET to identify nonresponders.
The American Society of Hematology's Journal of Blood is the most cited peer-reviewed publication in the field, featuring latest research on blood disorders. New articles will be made available online about three months ahead of print.